Research Funding Opportunity from CDMRP/PRMRP for Fiscal Year 25

In our ongoing effort to advance scientific understanding and advancing treatment research in all Fragile X-associated conditions and disorders, we are sharing information on an available funding opportunity.

Peer Reviewed Medical Research Program (PRMRP)

Over $21M has been awarded for Fragile X-associated conditions and disorders research since 2010, when Fragile X was first included as an eligible condition for funding from the Congressionally Directed Medical Research Program (CDMPR) Peer Reviewed Medical Research Program (PRMRP). Thanks to the efforts of the NFXF advocates, Fragile X, which includes all FMR1-associated conditions and disorders, is once again included as an eligible topic area for Fiscal Year 25 (FY25). The PRMRP is within the Department of Defense’s Congressionally Directed Medical Research Programs (CDMRP) – a global funding organization that fosters novel approaches to congressionally targeted biomedical research areas. CDMRP receives annual appropriations that are disease or condition-specific. Congress appropriated $150M in funding For the FY25 budget within the PRMRP.

Since 2010, the NFXF and the Fragile X community have continued to advocate in Congress for policies and research funding for Fragile X-associated conditions and disorders. We have nominated numerous consumer reviewers from the Fragile X community to participate in the peer and programmatic PRMRP review process. The consumer reviewer provides a perspective that is complementary to the scientific expertise and helps the scientist understand the human side of how the research will impact the Fragile X community.

Important Opportunities for Fiscal Year 25

• Rare Diseases and Conditions Portfolio – Fragile X syndrome and Fragile X-associated conditions and disorders are included in this category, which was introduced in FY24 and continues in FY25. **Hereditary ataxia is also listed as an eligible condition within the PRMRP, which may offer a potential additional option for FXTAS projects. Learn more here.
  
• Providing Feedback about Research Needs – The NFXF was honored to once again contribute to a strategic discussion with PRMRP program leadership, helping to identify critical research gaps and unmet needs within the Fragile X community. This input was instrumental in shaping the FY25 strategic goals and supports ongoing efforts to drive meaningful progress in research and the development of therapeutic interventions.
• Webinar with PRMRP Program Manager – The NFXF team is coordinating with the PRMRP Program Office to host an informational webinar. Additional details, including date and registration inforamtion, will be shared as soon as they are available.

FY25 PRMRP Funding Opportunities/Mechanisms for Fragile X-associated Conditions and Disorders Research:

• Clinical Trial Award: Supports the rapid implementation of clinical trials of novel interventions. The Preproposal deadline is June 9, 2025, 5:00 p.m. ET
• Technology/Therapeutic Development Award: Supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, and/or quality of life – Letter of Intent deadline is June 9, 2025, 5:00 p.m. ET

The NFXF can help facilitate your research!

The PRMRP program values collaborations between patient advocacy groups and researchers.

The NFXF Research Facilitation portfolio leverages our skills to create meaningful partnerships with all researchers, from initial concept through the dissemination of results. We support our research facilitation mission through the NFXF Research Readiness Program, our services menu, focused projects, and advocacy. We recommend all researchers engage in the program early for support from concept through the conclusion of the research project.

For additional information or to get started, please contact Anna De Sonia at research@fragilex.org.